Anika Therapeutics, Inc. (ANIK)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-05
$19.33-5.25%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-05
QuarterlyIQ Insights · ANIK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 71.5% |
| Our one-year growth estimate | diamond | 5.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 66.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 2 industry peers
ANIK — credit agreement
Dated 2026-07-14
Entry into a Material Definitive Agreement On July 10, 2026, we entered into a Fifth Amendment to Credit Agreement, or the Fifth Amendment, amending our existing revolving line of credit agreement dated October 24, 2017 with Bank of America, N.A., which revolving line of credit agreement, as amended to date (including by such Fifth Amendment), we refer to as the Amended Agreement. Under the Amended Agreement, Bank of America, N.A. serves as administrative agent, issuer of letters of credit an…
Why it matters: Q2 OEM growth came partly from order timing. Management warned that some OEM orders could make second-half results softer.
Watch forOEM revenue grows year over year in the second half, despite the order timing shifts.
Also watch forOEM revenue falls year over year in the second half, or misses the 2026 growth range of 0%–5%.
Why it matters: The FDA review timeline is uncertain. Anika removed Hyalofast revenue from its 2027 forecast. A clear review step would ease that uncertainty.
Watch forThe FDA clears the Hyalofast PMA or gives a clear next step without asking for new clinical work.
Also watch forThe FDA rejects the PMA, asks for new clinical work, or the review stalls with no clear next step.
Why it matters: Anika raised its 2026 revenue growth range to 5%–10%. Results near or above the low end would back that stronger outlook.
Supportive ifFull-year 2026 revenue growth is at least 5%, within the current 5%–10% range.
Worry ifFull-year 2026 revenue growth is below 5%.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$154 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $350 loss on $10,000 · 3.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,256 loss on $10,000 · 22.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.